Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | CTH | P32929 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19901566 | 0.83 | EGLN1 (0.39) | EGLN1CTHAPEX1ALDH1A1MAPT | |
| SCHEMBL11923002 | 0.78 | MAOA (0.41) | — | |
| SCHEMBL13140609 | 0.76 | LMNA (0.38) | ALDH1A1MAPTLMNA | |
| SCHEMBL27764506 | 0.76 | ALDH1A1 (0.34) | EGLN1SMN1; SMN2CYP2D6ALDH1A1 | |
| SCHEMBL31612137 | 0.75 | EGLN1 (0.33) | EGLN1SMN1; SMN2CTHTSHRLDHA | |
| Oxalic Acid SCHEMBL1052746 | 0.73 | POLB (0.34) | ALDH1A1KDM4E | |
| SCHEMBL9059109 | 0.73 | DGAT1 (0.34) | EGLN1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL13118699 | 0.72 | MEN1 (0.37) | ADRA1ATSHRALDH1A1LMNATDP1 | |
| SCHEMBL17177603 | 0.72 | NOS2 (0.32) | — | |
| SCHEMBL1287256 | 0.71 | EGLN1 (0.35) | EGLN1SMN1; SMN2HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119684406-A | Enzyme response self-assembled polypeptide prodrug loaded with camptothecine, preparation and application thereof | 东南大学 | 2025-03-25 | — | — | CN | disclosed |
| WO-2023150540-A1 | HYDROXAMIC ACID MACROCYCLIC AGENTS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-104650342-B | Highly branched chain polymeric drug precursor and its application | 江苏豪森药业集团有限公司 | 2018-07-10 | — | — | CN | disclosed |
| US-9650664-B2 | Use of photocleavable compounds | FEMTONICS KFT (HU) | 2017-05-16 | — | — | US | disclosed |
| CN-104650342-A | Highly-branched polymerized prodrug, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL | 2015-05-27 | — | — | CN | disclosed |
| US-20140234883-A1 | USE OF PHOTOCLEAVABLE COMPOUNDS | FEMTONICS KFT (HU) | 2014-08-21 | — | — | US | disclosed |
| EP-2763965-A2 | USE OF PHOTOCLEAVABLE COMPOUNDS | Femtonics Kft. (HU) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013050798-A2 | USE OF PHOTOCLEAVABLE COMPOUNDS | FEMTONICS KFT. (HU) | 2013-04-11 | — | — | WO | disclosed |
| EP-1758916-B1 | 3-BETA-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| EP-1512683-B1 | Novel opiate compounds, methods of making and methods of use | RES TRIANGLE INST (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20020193602-A1 | Novel opiate compounds, methods of making and methods of use | RESEARCH TRIANGLE INSTITUTE (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020169324-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RESEARCH TRIANGLE INSTITUTE (US) | 2002-11-14 | — | — | US | disclosed |
| US-20020165396-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RESEARCH TRIANGLE INSTITUTE (US) | 2002-11-07 | — | — | US | disclosed |
| EP-1061919-A4 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RES TRIANGLE INST (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1061919-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | Carrol, Frank Ivy (US) | 2000-12-27 | — | — | EP | disclosed |
| US-5990278-A | REACTING AN ORGANIC CARBOXYLIC ACID WITH AN AMINE DERIVATIVE CONTAINING A PROTECTIVE GROUP TO FORM PROTECTED CARBAMIDE, REACTING PROTECTED CARBAMIDE AT A FIRST PH TO SPLIT OFF PROTECTIVE GROUP, REACTING IN SECOND PH TO FORM CARBAMIDE | HOFFMANN STEFEN (DE) | 1999-11-23 | — | — | US | disclosed |
| WO-1999045925-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RESEARCH TRIANGLE INSTITUTE (US) | 1999-09-16 | — | — | WO | disclosed |
| EP-0506478-A1 | Piperidine derivatives | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
| CN-1048030-A | Promote the phenol derivatives of growth factor of human nerve | SANKYO CO (JP) | 1990-12-26 | — | — | CN | disclosed |
| EP-0399814-A2 | Phenol derivatives for promoting human nerve growth factor | Sankyo Company Limited (JP) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169324-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | OPRK1, OPRM1, OPRL1 | EGLN1 2784/4885SMN1; SMN2 2062/4885HMGCR 2451/4885 |
| US-20020193602-A1 | Novel opiate compounds, methods of making and methods of use | OPRK1, OPRM1, OPRL1 | EGLN1 2784/4885SMN1; SMN2 2062/4885HMGCR 2451/4885 |
| US-20020165396-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | OPRK1, OPRM1, OPRL1 | EGLN1 2784/4885SMN1; SMN2 2062/4885HMGCR 2451/4885 |
| US-20140234883-A1 | USE OF PHOTOCLEAVABLE COMPOUNDS | ERCC1, ERCC4, ERCC5 | EGLN1 1084/4885SMN1; SMN2 4211/4885HMGCR 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.